Sanofi and GlaxoSmithKline said clinical trials of their Covid-19 vaccine showed an insufficient immune response in older people, delaying its launch to late 2021 and marking a setback in the global fight against the pandemic.
A combination of Canadian drug developer Medicago’s experimental Covid-19 vaccine and a booster from Britain’s GlaxoSmithKline will enter a large study with more than 30,000 volunteers in 2020.
Germany-based CureVac NV published detailed interim Phase I data of the company’s Covid-19 vaccine candidate CVnCoV.
Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of the potential first-in-class human monoclonal antibody tezepelumab hit the primary endpoint in severe asthma.
Novartis’ IL-1β inhibitor Ilaris (canakinumab) came up short in a Phase III Covid-19 study, the company reported, following an interim analysis of data.
Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.
Leading pharmaceutical companies – including Moderna, Pfizer and AstraZeneca – are racing ahead to develop and distribute a Covid-19 vaccine.
Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
AstraZeneca’s Covid-19 vaccine accurately follows the genetic instructions programmed into AZD1222 by the developers to successfully provoke a strong immune response, according to a detailed analysis carried out by independent UK scientists.
Johnson & Johnson temporarily paused the company’s Covid-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest-profile efforts to contain the global pandemic.
